Please click here to see the latest news stories relating to Covid-19

Bionow members are welcome to submit PR items to this newsroom for all to see. Describing current activity and progress in the sector, it's a great place to promote your organisation and keep up to date with the latest developments.

Whether currently a member or not, also keep up to date with all the latest news and events by registering to receive the Bionow newsletter.

In March 2021, Cobra and Cognate officially joined the Charles River family and in January 2022, launched the rebranding of our businesses into Charles River.

The plasmids have been released at Cobra and are ready to be used as starting material for the GMP batch that will be used in the first clinical study scheduled to begin in 2022.

Process optimization and stability enhancement in scale-up manufacturing of AAV and lentiviral vectors through Albumedix' proprietary recombinant human albumin-based product

Cognate BioServices and its subsidiary Cobra Biologics have been acquired by Charles River

Cobra is undertaking a multi-phase augmentation of its plasmid DNA services as a continuation of its Advanced Therapy expansion project

Foundation for future commercial supply of CG01 secured with delivery of three Master Cell Banks

Providing large scale manufacturing capacity for AZD1222

ChAdOx1 consortium, led by the Jenner Institute, working to produce adenoviral vaccine with fast-tracked clinical trials to begin in April 2020

OPENCORONA consortium awarded €3million funding by Horizon 2020 to support emergency research and development against the COVID-19 outbreak

Developing world-leading capabilities in drug substance and drug product viral vector production for gene and immunotherapy.

ATMP (Advanced therapy medicinal product) specialist Cobra Biologics builds Sweden’s first 500 litre bioreactor investing €20 million at its Matfors facility in Sundsvall.

Cobra Biologics, an international contract development and manufacturing organisation with a focus on advanced therapy medicinal products has won a £1.5m shared grant from Innovate UK.

Our Valued Sponsors & Partners